Anthem Biosciences’ ₹3,395-crore IPO saw strong investor demand, with overall subscription at 63.86x, signaling robust interest in the pharma CDMO sector.

Anthem Biosciences' IPO ended on 16 July, with the issue booked over 60 times. Strong demand from qualified institutional ...

Anthem Biosciences' Rs 3,395 crore IPO was subscribed 63.86 times, exceeding expectations. QIBs showed strong interest, while ...

Anthem Biosciences Ltd's IPO was subscribed 63.86 times by closing day, driven by institutional buyers. The Rs 3,395-crore ...

Following the close of the subscription of initial public offering (IPO) of Anthem Biosciences Limited, all eyes of the ...

Anthem Biosciences Ltd, a CRDMO founded in 2006, offers end-to-end drug discovery-to-manufacturing services and specialises ...

Bengaluru-based Anthem Biosciences' initial public offering (IPO) has been subscribed nearly 10 times on its final day, indicating a 27% listing premium.

The Anthem Biosciences IPO, starting July 14, 2025, aims to raise ₹3,395 crore through an Offer for Sale of 5.96 crore shares by existing shareholders, without proceeds going to the company. Shares ...

Anthem Biosciences is selling its shares in the price band of Rs 540-570, applied for a minimum of 26 shares and its ...

Anthem Biosciences' IPO is seeing huge demand on its last day. The issue has been subscribed 1,400% so far, showing strong interest from all types of investors. At the same time, the GMP has jumped to ...

Anthem Biosciences IPO GMP surged on Wednesday as the Rs 3,395-crore initial share saw robust subscription on the concluding ...